Shots:
Cerevance has reported the P-III (ARISE) trial data assessing solengepras (75 or 150mg, QD, PO) vs PBO as an adjunct to levodopa & other PD medications in 341 PD pts (≥30yrs.) with motor fluctuations & ≥3hrs. of daily OFF time (91% pts completed the trial)
Solengepras (150mg) met the 1EP, reducing average daily OFF time…
